+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effects of dupilumab compared with placebo on airway inflammation, airway resistance, and lung remodeling in people aged 40 to 85 years with Chronic Obstructive Pulmonary Disease COPD. This Phase 4, multinational, randomized, double-blind, placebo-controlled study aims to understand how these changes relate to lung function, exacerbations, and quality of life improvements. Participants will receive subcutaneous injections of either dupilumab or placebo following the study protocol. The treatment period lasts up to 24 weeks within a total study duration of 40 weeks, during which participants will attend nine visits. The study includes detailed lung imaging assessments to measure mucus plugging and airway changes. During the study, participants will undergo evaluations including lung mucus scoring, high-resolution CT scans, and forced oscillation technique tests to monitor airway resistance and reactance. Safety is monitored by recording adverse events up to 36 weeks. The primary outcome is the change in global lung mucus score from baseline to Week 24. Participants will be followed for the full duration to assess treatment effects and safety.

Age: 40Years - 85YearsAll GendersPhase 4
85 locations